Meeting
2017 ASCO Annual Meeting
A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
Authors
Anuradha Krishnamurthy
University of Colorado-Denver, Aurora, CO
Anuradha Krishnamurthy , A. Dasari , Anne M. Noonan , Janice M. Mehnert , Albert C. Lockhart , Mark N. Stein , Hanna Kelly Sanoff , James J. Lee , Aaron Richard Hansen , Usha Malhotra , Sarah Rippke , Sarah Lindsey Davis , Wells A. Messersmith , S. Gail Eckhardt , Christopher Hanyoung Lieu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02188264
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2587)
DOI
10.1200/JCO.2017.35.15_suppl.2587
Abstract #
2587
Poster Bd #
79
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
First Author: Anuradha Krishnamurthy
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2013 ASCO Annual Meeting
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
First Author: Rebecca Suk Heist
Poster
2013 Gastrointestinal Cancers Symposium
![Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.](https://d201v5jt9ylckg.cloudfront.net/133/7677/79386/79386_poster_pv.jpg)
Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.
First Author: Howard Hochster